None listed
Conditions
Interventions
None listed
Sponsors
Seoul National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Male or female aged 20 years or older 2) Patients who received drug-eluting stent implantation for coronary artery disease and received combination antiplatelet therapy for 1 year (±6 months) (1 year (±6 months) is defined as 365 days ±180 days). 3) Patients who had no clinical events during the past 1 year (±6 months) of antiplatelet therapy 4) Patients who were confirmed to be using clopidogrel or aspirin as a single antiplatelet agent at the time of patient enrollment 5) Patients who received an explanation of this study and voluntarily signed a consent form 6) For women of childbearing potential, those who agreed to use appropriate contraception during the study period
Exclusion criteria
Exclusion criteria: 1) Patients with contraindications or hypersensitivity to antiplatelet agents (Clopidogrel or Aspirin) being treated 2) Patients who cannot discontinue existing antiplatelet agents 3) Patients with an expected life expectancy of less than 2 years 4) Patients with a current bleeding tendency or a history of major bleeding requiring discontinuation of antiplatelet agents 5) Patients scheduled to undergo procedures or surgeries requiring long-term discontinuation of antiplatelet agents during the study period 6) Patients who are pregnant or breastfeeding 7) Other patients who, in the investigator's judgment, are difficult to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of all-cause death, MI, stroke, major bleeding (BARC = type 3), readmission due to ACS, and urgent revascularization during the follow-up period | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of TVR/TLR (target vessel/lesion revascularization) during the follow-up period | — |
Countries
Korea, Republic of
Contacts
Public ContactHyo-soo Kim
Seoul National University Hospital
Outcome results
None listed